Oral anticoagulant therapy for early post-TAVI thrombosis

Abstract

While transcatheter aortic valve implantation (TAVI) is now the accepted treatment option of choice for patients presenting with severe symptomatic aortic stenosis who are deemed to be inoperable or of high surgical risk, there have been concerns regarding the risk of early valve failure and durability. One potential limitation is the occurrence of early post-TAVI thrombosis. Whilst the incidence of obstructive transcatheter heart valve (THV) thrombosis is <1 %, with technological advances in imaging, it is increasingly apparent that the overall true incidence is likely to be much higher with between 7-40 % of patients observed to have appearances strongly suggestive of asymptomatic subclinical THV thrombosis. This short review discusses the diagnosis of early THV thrombosis and the role of anticoagulation therapy for the management of these patients.

Antitrombozinio Gydymo Svarba Ir Parinkimas Po Transkateterinio Aortos Vožtuvo Implantavimo

“…Nepaisant sėkmingai atliktos procedūros, svarbu užtikrinti tolesnį antikoaguliacinį gydymą, siekiant išvengti vožtuvo trombozės. Pacientų, sergančių lėtine inkstų liga, sumažėja kairiojo skilvelio išmetimo frakcija, tad nesant antikoaguliacinio gydymo, didėja trombozės išsivystymo rizika [1]. Antitrombozinis gydymas po TAVI priklauso nuo keleto veiksnių.…”